As of the latest Form 4 filed Jun 12, 2026.
What Pacira BioSciences, Inc. insiders — officers, directors and 10% owners — have bought and sold in their own stock, straight from their SEC Form 4 filings. Values are shares × the reported transaction price where both are disclosed.
Buys plotted up, sells down; bar height is the disclosed dollar value (shares × reported price). Our Form 4 history is only complete from mid-2026, so early months are sparse — the series fills in as more filings land. Open-market purchases and sales only.
Newest filing first — the 22 most recent filings for PCRX.
| Filed | Trade date | Insider | Transaction | Shares | Price | Value | 10b5-1 | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-12 | 2026-06-11 | RIKER LAUREN Senior Vice President, Finance | SSale | −6.12K | $23.50 | $144K | Yes (planned) | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Hirawat Samit Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | CHRISTIE CHRISTOPHER Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Young Alethia Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | YANG MICHAEL J. Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | BIGAL MARCELO Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Froimson Mark Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-12 | 2026-06-10 | Brege Laura Director | AAward | +6.41K | $0.00 | $0.00 | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-04 | WILLIAMS KRISTEN Chief Administrative Officer | SSale | −10.3K | $22.27 | $228K | Yes (planned) | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | RIKER LAUREN Senior Vice President, Finance | FTax | −3.19K | $22.32 | $71.1K | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | SLONIN JONATHAN Chief Medical Officer | FTax | −4.73K | $22.32 | $106K | No | Form 4 ↗ |
| 2026-06-05 | 2026-06-03 | WILLIAMS KRISTEN Chief Administrative Officer | FTax | −8.53K | $22.32 | $190K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-23 | Cross Shawn Chief Financial Officer | SSale | −12.9K | $25.16 | $326K | Yes (planned) | Form 4 ↗ |
| 2026-04-24 | 2026-04-23 | Cross Shawn, Chief Financial Officer | MExercise | +12.9K | $16.45 | $213K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-22 | Cross Shawn Chief Financial Officer | SSale | −1.50K | $25.01 | $37.5K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-22 | Cross Shawn, Chief Financial Officer | MExercise | +1.50K | $16.45 | $24.7K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-21 | Cross Shawn, Chief Financial Officer | SSale | −2.85K | $25.01 | $71.2K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-21 | Cross Shawn, Chief Financial Officer | MExercise | +2.85K | $16.45 | $46.8K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Cross Shawn, Chief Financial Officer | SSale | −7.71K | $25.14 | $194K | Yes (planned) | Form 4 ↗ |
| 2026-04-22 | 2026-04-20 | Cross Shawn, Chief Financial Officer | MExercise | +7.71K | $16.45 | $127K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | SLONIN JONATHAN Chief Medical Officer | SSale | −3.26K | $22.82 | $74.4K | Yes (planned) | Form 4 ↗ |
| 2026-03-19 | 2026-03-17 | Froimson Mark Director | SSale | −500.00 | $21.81 | $10.9K | No | Form 4 ↗ |
Insiders — a company’s officers, directors and holders of more than 10% of its stock — must report any trade in that stock to the SEC on a Form 4 within two business days. Each row here is one transaction from those filings.
The transaction code tells you what happened: Purchase (P) and Sale (S) are open-market trades — the ones markets watch most; Award (A) is a granted stock or unit, Option exercise (M) converts options into shares, and Gift (G) is a transfer for no consideration. Awards, exercises and gifts are largely compensation or administrative, not a directional bet.
One caveat on sales: many are made under a Rule 10b5-1 plan scheduled months in advance, so a sale is not automatically a bearish signal. Insider activity is a noisy input — read it alongside the filings, not on its own.
See also PCRX’s full analysis or the market-wide insider trading feed. The tabs above jump to PCRX’s other SEC data.
Source: SEC Form 4 filings for PCRX, parsed from EDGAR. Transaction prices are as reported in the filing — SEC public-domain data, not market quotes. Values are shares × reported price where both are disclosed; grants and gifts often carry no price. A delayed record of what insiders reported, not a live position or a recommendation.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.